Enter valid email.
POSTED: March 02, 2017
Dr. Laurence Klotz talks about using molecular biomarkers to predict if your prostate cancer is too aggressive for active surveillance.
Tags: Ative Surveillance, Genomics, Molecular Genetics, Uncategorized,
Posted: Mar 02, 2017
May I ask what direction you decided to go into.
Posted: Jan 29, 2019
I recently found out when I had my yearly physical that my PSA was elevated and I was referred to a Urologist and was advised to have a biopsy taken. I completed this and 12 samples were taken. The results are as follows. Out of the 12 samples I had 4 places that showed cancer.
These were on the right side of the prostate and 3 of the locations were rated as Gleason 3 + 3 which equals 6. The 4th location was rated as Gleason 7 but that number was from 3 + 4 equals 7 not 4 + 3. It was noted in the pathology report that having a Gleason of 7 with 4 + 3 is more aggressive than my results of Gleason 7 from 3 + 4. The 8 other samples all showed negative and were on the left side of the prostate, My PSA was elevated to 4.8 and my Gleason score of 7 was considered to be intermediate risk. I am currently researching the options I have and have read all the side affects with each of the options. I have had the original Urologist who counseled me in the results of the biopsy after giving all the options, he suggested complete removal of the prostate and other tissues in or around the gland. The Oncologist that I saw and discussed all the options also advised of complete removal. I decided to get a second opinion which I have already scheduled an appointment of April 12, 2017. I am continuing to get as much research as I can in regards to the choices which have come from Mayo Clinic, John Hopkins and the University Of Hampton Proton Therapy in Hampton Va.
Posted: Mar 03, 2017
Posted: Nov 01, 2018
Posted: Dec 10, 2018